CliffBio
small molecule

GLIADEL

CARMUSTINE

Loss of exclusivity—loss of exclusivity
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameGLIADEL
Active ingredientCARMUSTINE
Strength7.7MG
Dosage formIMPLANT
RouteINTRACRANIAL
ModalitySmall molecule
FDA approvalSeptember 1996
Marketing statusRX

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.